{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:57Z","timestamp":1791685377591,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.neuropharm.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T14:48:13Z","timestamp":1447166893000},"page":"255-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model"],"prefix":"10.1016","volume":"101","author":[{"given":"Yanwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiZhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.10.002_bib1","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib2","first-page":"337","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J.\u00a0Park. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson's disease","volume":"211","author":"Bove","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jnr.22001","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth","volume":"87","author":"Buhren","year":"2009","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib7","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/aje\/kwm260","article-title":"Peripheral inflammatory biomarkers and risk of Parkinson's disease","volume":"167","author":"Chen","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","article-title":"The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer's disease","volume":"228","author":"Duffy","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2011.11.007","article-title":"Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice","volume":"674","author":"Faivre","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JAD-121888","article-title":"D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model","volume":"35","author":"Faivre","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt174","article-title":"Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP\/PS1 mouse model","volume":"5","author":"Faivre","year":"2013","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib13","first-page":"436813","article-title":"Parkinson's disease and systemic inflammation","volume":"2011","author":"Ferrari","year":"2011","journal-title":"Park. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FBP.0b013e32833c8544","article-title":"Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases","volume":"21","author":"Figueiredo","year":"2010","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib15","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1152\/jn.01161.2007","article-title":"Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid","volume":"99","author":"Gault","year":"2008","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0922-4106(91)90073-Q","article-title":"MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease","volume":"208","author":"Gerlach","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/WCO.0000000000000118","article-title":"Treatment of advanced Parkinson's disease","volume":"27","author":"Giugni","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib18","first-page":"65","article-title":"The role of MAO in MPTP toxicity\u2013a review","volume":"20","author":"Glover","year":"1986","journal-title":"J.\u00a0Neural Transm. Suppl."},{"issue":"19","key":"10.1016\/j.neuropharm.2015.10.002_bib19","first-page":"11","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J.\u00a0Neuroinflamm."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ncpneuro0924","article-title":"Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis","volume":"4","author":"Henchcliffe","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jalz.2013.12.009","article-title":"The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease","volume":"10","author":"Holscher","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases","volume":"42","author":"Holscher","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson's disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabet. Care"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib24","doi-asserted-by":"crossref","first-page":"7747","DOI":"10.1128\/MCB.02353-05","article-title":"Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation","volume":"26","author":"Hussain","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bcp.2006.06.013","article-title":"Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide","volume":"72","author":"Irwin","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib26","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm0509997","article-title":"GIP(Lys(16)PAL) and GIP(Lys(37)PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential","volume":"49","author":"Irwin","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jmcb\/mjs025","article-title":"Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes","volume":"4","author":"Jain","year":"2012","journal-title":"J.\u00a0Mol. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib28","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1097\/00001756-199511000-00023","article-title":"Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice","volume":"6","author":"Kano","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib29","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in\u00a0vitro and in\u00a0vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib30","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib31","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1194\/jlr.M006841","article-title":"GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene","volume":"51","author":"Kim","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib32","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/MCB.00325-07","article-title":"Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2","volume":"28","author":"Kim","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib33","doi-asserted-by":"crossref","first-page":"22297","DOI":"10.1074\/jbc.M500540200","volume":"280","author":"Kim","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0197-0186(87)90024-6","article-title":"The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's disease","volume":"11","author":"Kinemuchi","year":"1987","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: implications for research in Parkinson's disease","volume":"11","author":"Kopin","year":"1988","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F","article-title":"Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure","volume":"46","author":"Langston","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib39","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1471-4159.2010.06731.x","article-title":"Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells","volume":"113","author":"Li","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/18715273113126660155","article-title":"Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?","volume":"13","author":"Lima","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targ."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.regpep.2010.04.009","article-title":"The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets","volume":"165","author":"Lupi","year":"2010","journal-title":"Regul. Pept."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib42","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.3390\/ijms15045596","article-title":"Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide","volume":"15","author":"Maino","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib43","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.bbagen.2013.03.011","article-title":"A\u00a0novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores","volume":"1830","author":"Martin","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2010.03.002","article-title":"Case-control study of risk of Parkinson's disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan","volume":"293","author":"Miyake","year":"2010","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-007-0116-y","article-title":"Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation","volume":"9","author":"Moran","year":"2008","journal-title":"Neurogenetics"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.expneurol.2013.01.024","article-title":"Modeling dyskinesia in animal models of Parkinson disease","volume":"256","author":"Morin","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0304-3940(86)90282-X","article-title":"Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+","volume":"65","author":"Nakamura","year":"1986","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib48","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib49","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jnr.21349","article-title":"Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain","volume":"85","author":"Nyberg","year":"2007","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/187152411798047771","article-title":"Gastric inhibitory polypeptide and its receptor are expressed in the central nervous system and support neuronal survival","volume":"11","author":"Paratore","year":"2011","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pbb.2013.01.017","article-title":"Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism","volume":"104","author":"Park","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib53","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1999"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib54","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib55","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1301\/nr.2007.dec.S152-S156","article-title":"Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders","volume":"65","author":"Pradhan","year":"2007","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib56","doi-asserted-by":"crossref","first-page":"e114216","DOI":"10.1371\/journal.pone.0114216","article-title":"Behavioral phenotyping of Parkin-deficient mice: looking for early preclinical features of Parkinson's disease","volume":"9","author":"Rial","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2015.03.016","article-title":"Discovery of novel anti-parkinsonian effect of schisantherin A in in\u00a0vitro and in\u00a0vivo","volume":"593","author":"Sa","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","article-title":"Shared dysregulated pathways lead to Parkinson's disease and diabetes","volume":"19","author":"Santiago","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib59","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc10-1333","article-title":"Diabetes and the risk of developing Parkinson's disease in Denmark","volume":"34","author":"Schernhammer","year":"2011","journal-title":"Diabet. Care"},{"key":"10.1016\/j.neuropharm.2015.10.002_bib60","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"Eur. J. Neurosci."},{"issue":"Suppl.","key":"10.1016\/j.neuropharm.2015.10.002_bib61","first-page":"467","article-title":"Anti-apoptotic gene therapy in Parkinson's disease","author":"Schulz","year":"2006","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib62","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress","volume":"128","author":"Sharma","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.biopha.2015.01.029","article-title":"Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies","volume":"70","author":"Sharma","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0006-8993(97)00429-0","article-title":"Mitochondrial toxins in models of neurodegenerative diseases. I: in\u00a0vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions","volume":"765","author":"Smith","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib65","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/dom.12181","article-title":"A\u00a0novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents","volume":"16","author":"Tatarkiewicz","year":"2014","journal-title":"Diabet. Obes. Metab."},{"key":"10.1016\/j.neuropharm.2015.10.002_bib67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neulet.2008.03.026","article-title":"Association between AKT1 gene and Parkinson's disease: a protective haplotype","volume":"436","author":"Xiromerisiou","year":"2008","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081530126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081530126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:57:09Z","timestamp":1762214229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081530126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":67,"alternative-id":["S002839081530126X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.002","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}